AGL - Let's Play Q&A: Making a Case for "Why This Time Is Different" - Discipline, Data, and Execution

Research evidence excerpt

AGL - Let's Play Q&A: Making a Case for "Why This Time Is Different" - Discipline, Data, and Execution

ims paid. Cost pressure remains concentrated in Part B

52-Wk Range $81.73-$7.91 and inpatient spending, driven primarily by higher acuity and increased cost per admission

Market Cap ($M) $1,357 rather than utilization. While some categories such as oncology are not directly controllable,

management expects earlier clinical intervention, particularly in high risk conditions like ADTV 276,418

congestive heart failure, to reduce future cost intensity. AGL also increased Part D reserves Shares Out (M) 17 as a precaution ahead of reconciliation despite no change in underlying data, reflecting

Short Interest Ratio/% Of Float 6.8% a more conservative approach. At the same time, agilon is structurally reducing volatility

Dividend/Yield $0.00/0.0% through improved contract terms, including limiting tail risk and reducing exposure to

Enterprise Value ($M) $1,084 uncapped Part D risk, while enhanced claims visibility supports more reliable forecasting.

Cash & Equivalents ($M) $303

Earnings outlook and contracting. AGL’s increased earnings outlook is driven by Total Debt ($M) $30

improved risk capture, disciplined underwriting, and incremental contributions from new

contracts, though guidance embeds conservatism. agilon raised its 2026 risk score

14 Page Document assumption, reflecting better identification of previously under recognized conditions through

AI and expanded clinical programs, which should support both revenue and cost outcomes

over time. AGL’s new $200 mln national payer contract is being treated as breakeven

Reasons for this report despite being underwritten for positive returns, highlighting a cautious approach. The